Pulmonary metastasectomy for metastatic head and neck cancer prolongs survival significantly compared to non-surgical therapy.
Georg SchlachtenbergerFabian DoerrLeonie MengheshaMatthias B HeldweinPatrick LauingerPhilipp WolberJens Peter KlussmannThorsten WahlersKhosro HekmatPublished in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2022)
Patients with pulmonary metastatic HNC undergoing PM had a significantly better overall survival compared to patients receiving non-surgical therapy. Therefore, selected patients should undergo PM to improve survival.
Keyphrases
- pulmonary hypertension
- particulate matter
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- air pollution
- free survival
- newly diagnosed
- ejection fraction
- chronic kidney disease
- heavy metals
- polycyclic aromatic hydrocarbons
- prognostic factors
- stem cells
- risk assessment
- mesenchymal stem cells
- bone marrow
- cell therapy
- water soluble